13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839948
Total reported value
$4.2B
$4.2B
40 檔
24.3%
In Q3 2025, TCG Crossover Management, LLC's U.S. equity holdings reached a combined market value of $4.2B, distributed across 40 disclosed stock positions.
TCG Crossover Management, LLC executed strategic sector rebalancing during Q3 2025, establishing 13 new positions while fully exiting 10 holdings and trimming 5 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 29.70% | -1.41% | +17.42% | |
| 2 | CGON | Cg Oncology Inc | Stock-Other | 7.27% | -0.84% | — | |
| 3 | COGT | Cogent Biosciences Inc | Stock-Other | 4.80% | -0.93% | -2.39% | |
| 4 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 4.17% | +0.22% | +5.05% | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.74% | -4.87% | EXIT | |
| 6 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.53% | +0.52% | -20.49% | |
| 7 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.52% | -0.01% | +15.00% | |
| 8 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.25% | -0.10% | +11.65% | |
| 9 | TRML | Tourmaline Bio Inc | Stock-Other | 3.09% | — | -11.22% | |
| 10 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.87% | +0.07% | +22.53% | |
| 11 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.82% | — | +105.17% | |
| 12 | EYPT | Eyepoint Inc | Stock-Other | 2.50% | — | — | |
| 13 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.38% | -1.15% | EXIT | |
| 14 | SVRA | Savara Inc | Stock-Other | 2.17% | -0.10% | — | |
| 15 | RAPT | Rapt Therapeutics Inc | Stock-Other | 2.08% | — | — | |
| 16 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.99% | -1.07% | — | |
| 17 | UPB | Upstream Bio Inc | Stock-Other | 1.96% | -0.05% | EXIT | |
| 18 | LQDA | Liquidia CORP | Stock-Other | 1.91% | -0.44% | EXIT | |
| 19 | IRON | Disc Medicine Inc | Stock-Other | 1.51% | -0.09% | — | |
| 20 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.46% | -0.19% | EXIT | |
| 21 | XNCR | Xencor Inc | Stock-Other | 1.41% | +0.10% | — | |
| 22 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.36% | -0.17% | — | |
| 23 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.00% | -0.07% | — | |
| 24 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.99% | — | — | |
| 25 | KRRO | Korro Bio Inc | Stock-Other | 0.98% | — | — | |
| 26 | KOD | Kodiak Sciences Inc | Stock-Other | 0.92% | -0.23% | — | |
| 27 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.91% | +1.32% | — | |
| 28 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.77% | +0.34% | — | |
| 29 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.70% | -0.21% | EXIT | |
| 30 | ARVN | Arvinas Inc | Stock-Other | 0.68% | -0.58% | — | |
| 31 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.61% | +0.24% | — | |
| 32 | MBX | Mbx Biosciences Inc | Stock-Other | 0.56% | +0.30% | — | |
| 33 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.47% | -0.04% | EXIT | |
| 34 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.46% | +0.70% | — | |
| 35 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.37% | — | -7.14% | |
| 36 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.30% | +1.02% | — | |
| 37 | ✓ | Adc Therapeutics SA | Stock-Other | 0.27% | -0.93% | — | |
| 38 | PEPG | Pepgen Inc | Stock-Other | 0.27% | — | — | |
| 39 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.17% | -0.64% | — | |
| 40 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +24.5% | +17.42% | Add |
| 2 | TNGX | Tango Therapeutics Inc | +1.5% | -20.49% | Trim |
| 3 | AMLX | Amylyx Pharmaceuticals Inc | +1.3% | +5.05% | Add |
| 4 | KOD | Kodiak Sciences Inc | +0.5% | — | Unchanged |
| 5 | FULC | Fulcrum Therapeutics Inc | +0.3% | — | Unchanged |
| 6 | TRML | Tourmaline Bio Inc | 0% | -11.22% | Trim |
| 7 | VTYXUSD | Ventyx Biosciences Inc | — | — | Unchanged |
| 8 | MBX | Mbx Biosciences Inc | -0.1% | — | Unchanged |
| 9 | EYPT | Eyepoint Inc | -0.1% | — | Unchanged |
| 10 | AVTX | Avalo Therapeutics Inc | -0.2% | — | Unchanged |
| 11 | UPB | Upstream Bio Inc | -0.4% | -24.44% | Trim |
| 12 | SLN | Silence Therapeutics Plc-adr | -0.4% | — | Unchanged |
| 13 | VTGN | Vistagen Therapeutics Inc | -0.4% | — | Unchanged |
| 14 | DNTH | Dianthus Therapeutics Inc | -0.5% | +11.65% | Add |
| 15 | TRDA | Entrada Therapeutics Inc | -0.6% | — | Unchanged |
| 16 | AVU0 | Adverum Biotechnologies Inc | -0.7% | -7.14% | Trim |
| 17 | COGT | Cogent Biosciences Inc | -0.9% | -2.39% | Trim |
| 18 | DYN | Dyne Therapeutics Inc | -0.9% | +22.53% | Add |
| 19 | CATBUSD | Astria Therapeutics Inc | -1% | — | Unchanged |
| 20 | GPCR | Structure Therapeutics Inc | -1.1% | — | Unchanged |
| 21 | IRON | Disc Medicine Inc | -1.6% | — | Unchanged |
| 22 | TYRA | Tyra Biosciences Inc | -1.7% | — | Unchanged |
| 23 | OCUL | Ocular Therapeutix Inc | -1.8% | +15.00% | Add |
| 24 | 260 | Centessa Pharmaceuticals-adr | -1.9% | +8.50% | Add |
| 25 | XNCR | Xencor Inc | -2.2% | — | Unchanged |
| 26 | SVRA | Savara Inc | -2.5% | — | Unchanged |
| 27 | CGON | Cg Oncology Inc | -5% | — | Unchanged |
| 28 | AGIO | Agios Pharmaceuticals Inc | — | NEW | New buy |
| 29 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 30 | MLYS | Mineralys Therapeutics Inc | — | EXIT | Sold out |
| 31 | LQDA | Liquidia CORP | — | NEW | New buy |
| 32 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 33 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 34 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 35 | KRRO | Korro Bio Inc | — | NEW | New buy |
| 36 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 37 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 38 | ✓ | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 39 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 40 | ARVN | Arvinas Inc | — | NEW | New buy |
| 41 | MNPR | Monopar Therapeutics Inc | — | NEW | New buy |
| 42 | CMPS | Compass Pathways PLC | — | EXIT | Sold out |
| 43 | RLAY | Relay Therapeutics Inc | — | NEW | New buy |
| 44 | KURA | Kura Oncology Inc | — | EXIT | Sold out |
| 45 | ✓ | Third Harmonic Bio Inc | — | EXIT | Sold out |
| 46 | ✓ | — | EXIT | Sold out | |
| 47 | ✓ | Adc Therapeutics SA | — | NEW | New buy |
| 48 | PEPG | Pepgen Inc | — | NEW | New buy |
| 49 | NKTREUR | Nektar Therapeutics | — | EXIT | Sold out |
| 50 | CABA | Cabaletta Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, TCG Crossover Management, LLC reported a total U.S. public equity portfolio value of $4.2B across 40 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, CGON, COGT) accounted for 24.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
AGIO
市值: $57.4M
Top Position Liquidated / Trimmed
MLYS
前期市值: $39.2M
During Q3 2025, TCG Crossover Management, LLC's top holdings by market value included ABVX (29.7%)、CGON (7.3%)、COGT (4.8%). The largest single position, ABVX, represented 29.7% of total portfolio value.
In Q3 2025, TCG Crossover Management, LLC made 34 total portfolio adjustments, initiating 13 new buys, adding to 6 positions, trimming 5 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.